FDA Approves At-Home Test for Breast Cancer  The biotech company 23andMe was given the green light to send customers the test , which gives them a report about three BRCA1/BRA2 gene mutations. The CDC says the BRCA mutations tend to be present in about 2 percent of Ashkenazi Jewish women. Donald St. Pierre, the FDA's acting director, in news release The at-home test will help women learn about their family history of breast cancer and should be followed with doctor-ordered tests.